FDA Drug-Recall Velocity →

A pharmaceutical supply-chain compliance agent pulls ADW-219 weekly; when recall_velocity_score climbs above 40 (currently reading a low 12.5) and class_I_90d shows a rising count of FDA Class-I drug recalls — the most severe category, involving life-threatening risk — the agent cross-references the source_lineage (openFDA Drug Enforcement endpoint) against the company's active-ingredient supplier database, flags any supplier overlap, and generates a draft FDA Form 483 response checklist. The 90-day trailing window in methodology_version is calibrated to precede consent-decree and import-alert timelines, giving the compliance team a 4–8 week window to audit suppliers before enforcement escalates. Acting on a recall-velocity trend rather than a single high-profile recall catches the systemic quality-system failures that precede a cluster.

A director of regulatory affairs at a specialty pharma company uses ADW-219 to set the cadence and scope of supplier quality audits. When Class-I drug recall velocity is low (current score 12.5), routine audit schedules hold; when the velocity score rises into the 30–50 range, the director accelerates audits for API suppliers in the same therapeutic categories driving the recall spike, and briefs the CMO before the next board risk-committee meeting. This replaces a manual monthly review of FDA MedWatch emails that typically surfaced only the highest-profile individual recalls, missing the pattern of accelerating enforcement that presages broader industry-wide FDA actions.